Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13040868 | 0.88 | MEN1 (0.43) | MEN1KMT2AEPHX2ALDH1A1KDM4E | |
| SCHEMBL13077962 | 0.81 | EPHX2 (0.49) | EPHX2LMNAGAAOPRM1OPRD1 | |
| SCHEMBL13077601 | 0.78 | KMT2A (0.52) | MEN1KMT2AALDH1A1KDM4ELPAR1 | |
| SCHEMBL13077829 | 0.77 | EPHX2 (0.53) | MEN1KMT2AEPHX2ALDH1A1KDM4E | |
| SCHEMBL13078016 | 0.76 | EPHX2 (0.44) | EPHX2LMNAGAAOPRM1 | |
| SCHEMBL13077564 | 0.76 | LMNA (0.46) | EPHX2LMNAGAAOPRM1OPRD1 | |
| SCHEMBL13077652 | 0.75 | EPHX2 (0.45) | EPHX2LMNAGAAOPRM1OPRK1 | |
| SCHEMBL13077579 | 0.75 | CASR (0.46) | MEN1KMT2AEPHX2LMNAGAA | |
| SCHEMBL13077941 | 0.74 | CASR (0.48) | EPHX2LMNAGAAOPRM1OPRK1 | |
| SCHEMBL13077649 | 0.74 | LMNA (0.42) | MEN1KMT2AEPHX2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-11-04 | — | — | US | disclosed |
| WO-2008019690-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | C1R, C3AR1, PTH1R | MEN1 202/4885KMT2A 4121/4885EPHX2 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.